Chronic Bacterial Prostatitis Caused by Intracellular Bacteria (C. trachomatis or Mycoplasma spp.)
When chronic bacterial prostatitis is driven by obligate intracellular organisms — Chlamydia trachomatis or Mycoplasma species — pathogen identification is the critical step. Standard empirical treatment for conventional urinary bacteria is not appropriate in this setting; a targeted approach is required.
Intracellular bacteria — C. trachomatis or Mycoplasma spp. — have been identified as the causative pathogen of chronic bacterial prostatitis. This microbiological finding changes the treatment strategy.
Evidence supports antibiotic classes capable of intracellular penetration — specifically macrolides or tetracyclines — rather than fluoroquinolones, which have shown lower cure rates for obligate intracellular pathogens in this setting. The complete structured regimen is available via the protocol below.
Cessation of prostatitis symptoms and microbiological eradication of the causative intracellular pathogen.
References
- Prescribe a macrolide (e.g. azithromycin) or a tetracycline (e.g. doxycycline) if intracellular bacteria have been identified as the causative agent of CBP.
- If intracellular bacteria have been detected, macrolides or tetracyclines should be given.
- Azithromycin and doxycycline are active against atypical pathogens such as C. trachomatis and genital Mycoplasma spp.
- In patients with CBP caused by obligate intracellular pathogens, macrolides showed higher microbiological and clinical cure rates compared to fluoroquinolones.
- In asymptomatic post-treatment patients, routine urinalysis and/or urine culture is not mandatory as there are no validated tests of cure for bacterial prostatitis except for cessation of symptoms.